Abstract
Bacterial respiratory infections are the main reason of morbidity and mortality among cystic fibrosis (CF) patients. In early childhood, the respiratory infections are due to Staphylococcus aureus and Haemophilus influenzae. In older CF patients, pathogenic Gram-negative bacteria like Achromobacter xylosoxidans, Burkholderia cepacia complex and especially Pseudomonas aeruginosa are more frequently seen. P. aeruginosa is a turning point in the respiratory disease in CF and its predominance increases with age. Bacteria use a variety of two-component systems (TCS) to differentially express virulence factors involved in both acute and chronic infections. Here, we review bacterial TCS as targets for antibacterial treatment for CF patients.
Keywords: Bacterial infections, cystic fibrosis, two-component systems, antibacterial treatment, respiratory infection, pathogen.
Graphical Abstract
Current Drug Targets
Title:Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients
Volume: 18 Issue: 6
Author(s): Nadya Velikova*Jerry M. Wells
Affiliation:
- Host-microbe Interactomics Group, Department of Animal Sciences, Wageningen University, Wageningen,Netherlands
Keywords: Bacterial infections, cystic fibrosis, two-component systems, antibacterial treatment, respiratory infection, pathogen.
Abstract: Bacterial respiratory infections are the main reason of morbidity and mortality among cystic fibrosis (CF) patients. In early childhood, the respiratory infections are due to Staphylococcus aureus and Haemophilus influenzae. In older CF patients, pathogenic Gram-negative bacteria like Achromobacter xylosoxidans, Burkholderia cepacia complex and especially Pseudomonas aeruginosa are more frequently seen. P. aeruginosa is a turning point in the respiratory disease in CF and its predominance increases with age. Bacteria use a variety of two-component systems (TCS) to differentially express virulence factors involved in both acute and chronic infections. Here, we review bacterial TCS as targets for antibacterial treatment for CF patients.
Export Options
About this article
Cite this article as:
Velikova Nadya*, Wells M. Jerry, Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients, Current Drug Targets 2017; 18 (6) . https://dx.doi.org/10.2174/1389450117666160208145934
DOI https://dx.doi.org/10.2174/1389450117666160208145934 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
Current Cancer Drug Targets Targeting PI3K by Natural Products: A Potential Therapeutic Strategy for Attention-deficit Hyperactivity Disorder
Current Neuropharmacology Role of NUCB2/nesfatin-1 as a Possible Biomarker
Current Pharmaceutical Design Mice with Liver Composed of Human Hepatocytes as an Animal Model for Drug Testing
Current Drug Discovery Technologies Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Melatonin Could Be Beneficial in SARS-CoV-2 Therapy
The Natural Products Journal Recent Advances in Iron-Catalyzed C-H Bond Activation Reactions
Current Inorganic Chemistry (Discontinued) Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology Microbiology of the Human Intestinal Tract and Approaches for Its Dietary Modulation
Current Pharmaceutical Design Editorial [Hot topic:Food Addiction & Obesity Treatment Development (Executive Guest Editors: Mark S. Gold and Noni A. Graham)]
Current Pharmaceutical Design Mammalian Homologues of the Drosophila melanogaster flightless I Gene Involved in Early Development
Current Genomics The Clinical Characteristics and Survival Profiles of Wilms Tumor in the United Arab Emirates: A Single-center Retrospective Analysis
New Emirates Medical Journal Quality of Life of Children with Type 1 Diabetes: A Systematic Review
Current Diabetes Reviews Prevention and Treatment of Cardiovascular Disease in Adolescents and Adults through the Transcendental Meditation® Program: A Research Review Update
Current Hypertension Reviews Peripheral Biomarkers to Assess Suicide Risk
Current Psychiatry Reviews Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Crosstalk Between The Immune Receptors and Gut Microbiota
Current Protein & Peptide Science Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
Current Pharmaceutical Design Molecular Imaging: Its Application In Cardiovascular Diagnosis
Current Pharmaceutical Design